Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P306. Analysis of psychological and psychosocial impairment factors in patients with inflammatory bowel disease
Authors:

E. Krauss1, K. Hake2, A. Kleist3, J. Peirano4, T. Krause5, R. Ehehalt6, P. von Arnauld de la Perriere7, J. Buening8, O. Treml9, B. Siegmund10, C. Maaser11, B. Bokemeyer12, D.C. Baumgart10, M. Neurath1, J. Mudter1, 1University of Erlangen-Nuremberg, Department of Medicine 1, Erlangen, Germany, 2Medical Faculty of the University of Rostock, Clinic for Psychosomatic and Psychotherapeutic Medicine, Rostock, Germany, 3University of Erlangen-Nuremberg, Department of Medicine 1, D-91054 Erlangen, Germany, 4Psychotherapeutic clinic with a focus on IBD, Hamburg, Germany, 5Gastroenterological clinic, Kassel, Germany, 6University Hospital Heidelberg, Department of Medicine IV, Heidelberg, Germany, 7Gastroenterological clinic, Hamburg, Germany, 8University Clinic Schleswig-Holstein, Luebeck, Germany, 9FC Hagen-Gastroenterology, Hagen, Germany, 10Charité – University Berlin, Berlin, Germany, 11Municipal Hospital of Lueneburg, Lueneburg, Germany, 12Gastroenterological Clinic, Minden, Germany

P306. Apheresis efficacy in ulcerative colitis
P306. Efficacy and safety of low-molecular weight heparin for the prevention of venous thromboembolism in patients with severe ulcerative colitis
P306

Embedding pharmaceutical care into the multidisciplinary team

Authors:

A. St.Clair Jones*1, M. Smith2

1Brighton and Sussex University Hospitals NHS Trust, Pharmacy, Brighton, United Kingdom, 2Brighton and Sussex University Hospitals NHS Trust, Gastroenterology, Brighton, United Kingdom

P307.

Treatment preferences of patients with Crohn's disease candidates for anti-TNF treatment. A conjoint analysis (IMPLICA study)

Authors:

N. Borruel1, C. Taxonera2, J. Castro3, L. Rodríguez-San Pedro4, M. Costi5, S. Riestra6, F. Casellas1, 1Hospital Vall d'Hebron, Crohn's and Colitis Attention Unit. Digestive System Research Unit, Barcelona, Spain, 2Hospital Clinico San Carlos, Department Gastroenterology, Madrid, Spain, 3Hospital Arquitecto Marcide Ferroll, Gastroenterology, Ferroll, Spain, 4AbbVie Deutschland GmbH & Co, KG, GPRD, Ludwigshafen, Germany, 5Abbvie, Medical Department, Madrid, Spain, 6Hospital Central de Asturias, Department Gastroenterology, Oviedo, Spain

P307. A survey of patient opinion regarding the tolerability of, adherence to and efficacy of colesevelam compared with cholestyramine in the treatment of diarrhoea following ileal resection in Crohn's disease
P307. Age at diagnosis 40-years is not an accurate predictor of disease outcome in patients with Crohn's disease
Authors:

B.D. Lovasz1, L. Lakatos2, P.A. Golovics1, A. Horvath3, I. Szita2, T. Pandur2, M. Mandel1, Z. Vegh1, G. Mester4, M. Balogh4, C. Molnar5, E. Komaromi6, L.S. Kiss1, P. Lakatos1, 1Semmelweis University, 1st Department of Medicine, Budapest, Hungary, 2Csolnoky F. Province Hospital, 1st Department of Medicine, Veszprem, Hungary, 3Csolnoky F. Province Hospital, Department of Pediatrics, Veszprem, Hungary, 4Grof Eszterhazy Hospital, Papa, Hungary, 5Magyar Imre Hospital, Ajka, Hungary, 6Municipal Hospital, Varpalota, Hungary

P307. The clinical course of rectovaginal fistulas in Crohn's disease since the introduction of anti TNF drugs
P307

Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single center cohort study

Authors:

K. Risager Christensen*, C. Steenholdt, J. Brynskov

Herlev University Hospital, Department of Gastroenterology, Copenhagen, Denmark

P308.

Treatment of corticosteroid naive children and adolescents with ulcerative colitis by adsorptive depletion of myeloid lineage leucocytes as monotherapy or in combination with low dose prednisolone after failure of first-line medications

Authors:

T. Tanaka, S. Sugiyama, H. Goishi, T. Kajihara, M. Akagi, T. Miura, Akitsu Hospital, Gastroenterology, Hiroshima, Japan

P308. Advanced endoscopy for prediction of relapse in ulcerative colitis
Authors:

A. Jauregui-Amezaga1, M. Lopez-Ceron1, M. Aceituno1, M. Jimeno2, C. Rodriguez de Miguel1, E. Sanabria1, P. Susana1, M. Zabalza1, M. Sans1, E. Ricart1, I. Ordas1, B. Gonzalez1, M. Cuatrecasas2, J. Llach1, J. Panés1, M. Pellise1, 1Hospital Clínic i Provincial, Gastroenterology, Barcelona, Spain, 2Hospital Clínic i Provincial, Anatomical Pathology, Barcelona, Spain

P308. Low levels of glucocorticoid use in early Crohn's disease in Germany
P308. Parent–adolescent agreement regarding emotional and behavioral symptoms among adolescents with inflammatory bowel disease and population-based controls
P308

Interobserver agreement in assessment of Rutgeerts' score of endoscopic recurrence of ileal Crohn's disease: a substudy of the TOPPIC trial

Authors:

N.A. Kennedy*1, H. Ennis2, D.R. Gaya3, C. Mowat4, I.D.R. Arnott1, on behalf of TOPPIC Trial Investigators1, J. Satsangi1

1Western General Hospital, Gastrointestinal Unit, Edinburgh, United Kingdom, 2University of Edinburgh, Edinburgh Clinical Trials Unit, Edinburgh, United Kingdom, 3Glasgow Royal Infirmary, Gastroenterology, Glasgow, United Kingdom, 4Ninewells Hospital & Medical School, Gastroenterology, Dundee, United Kingdom

P309.

Transition experience from inpatient to ambulatory IBD care: Results of a pilot study

Authors:

A. Romanova1, D. Armstrong1, U. Chauhan1, S. Halder1, S. Kelly2, P. Moayyedi1, F. Tse1, J. Marshall1, 1McMaster University, Gastroenterology, Hamilton, Canada, 2McMaster University, General Surgery, Hamilton, Canada

P309. Adherence to 5-aminosalicylic acid therapies in ulcerative colitis: a United Kingdom budget impact analysis
Authors:

A. Szende1, D. Neves2, J. McDermott2, L. Yen3, 1Covance, Leeds, United Kingdom, 2Covance, Gaithersburg, MD, United States, 3Shire Development LLC, Wayne, PA, United States

P309. Interest of apheresis (Adacolumn®) in the treatment of ulcerative colitis
P309. Paradoxical inflammation, inflammatory bowel disease and infliximab
P309

The effects of preoperative adsorptive leukocytapheresis on inflammatory cytokines and septic complications after restorative proctocolectomy for ulcerative colitis: a prospective randomized study

Authors:

T. Yamamoto*, T. Shimoyama, K. Matsumoto

Yokkaichi Hazu Medical Centre, Inflammatory Bowel Disease Centre, Yokkaichi, Japan

P310.

Toxicity of thiopurines in patients with inflammatory bowel disease: Frequency and risk factors

Authors:

N. Ben Mustapha1, A. Labidi1, M. Serghini1, M. Fekih1, J. Boubaker1, A. Filali1, 1La Rabta Hospital, Gastroenterology A, Tunis, Tunisia